Epoxomicin and the Evolution of Translational Ubiquitin-P...

2026-01-19

This thought-leadership article, authored from the perspective of APExBIO’s scientific marketing team, provides translational researchers with an in-depth, mechanistically-driven exploration of Epoxomicin as a selective, irreversible 20S proteasome inhibitor. It contextualizes emerging viral-host interaction research, integrates best practices in experimental design, and delivers strategic guidance for advancing ubiquitin-proteasome pathway studies—escalating the conversation beyond standard usage guides and product descriptions.